| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President And CEO
1 company
Sibold William John is a President And CEO at MDGL. Recent filings cover 0 purchases and 16 sales. Those positions are worth an estimated $107.1M at current prices.
Our model assigns Sibold William John a below-average insider score of 24/100, based on 5 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -67.2%.
Sibold William John's largest disclosed position is in MDGL as President And CEO, worth about $107.1M. The recent filings there lean toward selling, a net 27,742 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | President And CEO | Sale+OE | 2,500 | $547.30 | $1,368,253.45 | -0.1% | - | - | |
| Dec 4, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | President And CEO | Sale+OE | 2,400 | $575.34 | $1,380,816.00 | -1.6% | -25.8% | - | |
| Sep 9, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | President And CEO | Sell | 7,279 | $445.63 | $3,243,740.77 | -6.6% | +26.7% | - | |
| Aug 21, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | President And CEO | Sell | 7,616 | $400.18 | $3,047,756.37 | -3.3% | +36.5% | - | |
| Jan 24, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | President And CEO | Sell | 1,584 | $335.24 | $531,020.16 | -2.8% | -2.5% | +46.4% | |
| Sep 9, 2024 | MDGL Madrigal Pharmaceuticals, Inc. | President And CEO | Sell | 6,363 | $243.83 | $1,551,490.29 | -10.2% | +33.4% | +88.0% |